NICE has issued draft guidance this week turning down two treatments for patients with advanced renal cell carcinoma.
Kisplyx (lenvantinib) in combination with everolimus has been turned down for previously treated patients due to uncertainties with the clinical evidence.
Fotivda (tivozanib) has been rejected as a first line treatment due to uncertainties on whether the drug increases overall length of survival.
